North America Genomics Market size was valued at USD 26,800 Million in 2025 and is expected to reach USD 71,200 Million at a CAGR of 9.2% from 2024 to 2035.
The economic impact of tariffs on "North America Genomics Market".
North America Genomics Market Growth Drivers
Rising adoption of precision medicine is significantly driving the genomics market in North America. Leading hospital networks and research institutions such as the Mayo Clinic are increasingly integrating genomic data into their clinical practices to provide personalized treatment. The surge in government initiatives, such as the NIH’s All of Us Research Program, has accelerated large-scale genomic studies. These steps allow for better diagnosis, targeted therapies, and improved patient outcomes, ensuring higher demand for genomic sequencing, analysis, and related services.
Increasing investment in genomics R&D by major biopharma companies is fueling market growth. For instance, Illumina, a key genomics company, recently expanded its product line with the launch of NovaSeq X Series, a next-generation sequencing platform, enhancing data throughput and research scalability. Such technological advancements are making genomics research more accessible and cost-effective for biotech firms and research organizations, leading to substantial market expansion across the region.
North America Genomics Market Trends
Integration of artificial intelligence (AI) and machine learning with genomics is becoming a game-changer. Companies like NVIDIA and Deep Genomics are providing AI-powered platforms to analyze massive genome datasets efficiently. These tools allow for faster and more accurate variant interpretation, disease gene identification, and prediction of drug response, streamlining research and boosting clinical adoption. The continuous development in computational genomics is expected to transform drug discovery and personalized medicine in the coming years.
Increasing focus on consumer genomics and direct-to-consumer (DTC) testing continues to reshape the North American genomics landscape. Firms like 23andMe and AncestryDNA have made genetic testing accessible to millions, encouraging consumer participation in genetic health and ancestry tracing. This trend is expanding market reach beyond clinical and research settings, fostering greater public awareness and engagement in genomics while generating large volumes of data for further research and insights.
North America Genomics Market Opportunities
Growing utilization of genomics in agriculture and food safety is a promising opportunity. Companies like Corteva Agriscience are leveraging genomic tools to develop high-yield, disease-resistant crops. This not only enhances food security but also contributes to sustainable farming practices, tapping into lucrative agri-genomics market segments.
Expansion of genomic data-sharing networks creates opportunities for collaborative research. Initiatives such as the Global Alliance for Genomics and Health are enabling cross-institutional studies, accelerating discoveries and translational medicine.
North America Genomics Market Revenue (USD Million), 2020-2035
The market revenue for North America's genomics sector shows strong and sustained growth from 2020 to 2035. Starting at USD 12,300 Million in 2020, the market rises steadily each year, fueled by technological advancements, increased R&D investments, and expanded clinical applications. By 2025, revenue is projected to reach USD 26,800 Million, and by 2030, it’s estimated at USD 41,700 Million. By 2035, the market is expected to achieve USD 71,200 Million in revenue, reflecting a robust CAGR. This sustained growth demonstrates the increasing importance and adoption of genomics in healthcare, research, and adjacent sectors.
North America Genomics Market Share by Region (%), 2025
In 2025, the United States dominates the genomics market in North America, capturing 82% of the regional market share due to its advanced infrastructure, major research organizations, and a robust ecosystem of genomics companies. Canada accounts for 12%, driven by strong academic and healthcare research, while Mexico holds a 4% share owing to increasing adoption of genomic technologies. The combined share of smaller countries and regions, such as Bermuda and others, stands at 2%. This regional distribution underscores the U.S.'s leadership in the genomics space and the growing relevance of other North American markets.
Recent Developments in North America Genomics Market
In May 2024, Illumina announced the acquisition of Singular Genomics, a move aimed at consolidating sequencing platforms and expanding technology offerings for clinical and research genomics customers. This deal strengthens Illumina's market leadership and drives adoption of advanced sequencing solutions across North America.
In June 2024, 23andMe received FDA clearance for a new Pharmacogenomics Report, empowering consumers with information about how their genetics may impact their response to medications. This milestone highlights the growing regulatory acceptance of consumer genomics and its applications in personalized medicine.
In April 2024, Thermo Fisher Scientific launched the Ion Torrent Genexus Integrated Sequencer, which automates the genomic workflow from sample preparation to data interpretation. This advancement significantly reduces the turnaround time for clinical genomic testing, facilitating broader usage in oncology and genetic disease diagnostics.
Press Releases